Buscar
Longeveron Inc
LGVNAñadir a la lista de seguimiento
3.300USD
+0.460+16.20%
Cierre 11-11 16:00（ET）
10.53MCap. mercado
PérdidaP/E TTM
Acerca de Longeveron Inc Compañía
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Perfil de Longeveron Inc
Símbolo de cotizaciónLGVN
Nombre de la empresaLongeveron Inc
Fecha de salida a bolsaFeb 12, 2021
Director ejecutivoPowell (Than)
Número de empleados25
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 12
Dirección1951 NW 7th Ave
CiudadMIAMI
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33136
Teléfono13053027158
Sitio Webhttps://www.longeveron.com/
Símbolo de cotizaciónLGVN
Fecha de salida a bolsaFeb 12, 2021
Director ejecutivoPowell (Than)
Ejecutivos de Longeveron Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
57.73K
-5.05%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
56.43K
-3.52%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
54.71K
-4.61%
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
54.25K
+52.72%
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
33.27K
-6.76%
Mr. Nirav S. Jhaveri
Mr. Nirav S. Jhaveri
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
29.26K
-2.54%
Ms. Marie Washburn
Ms. Marie Washburn
Chief Financial Officer, Senior Vice President, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Senior Vice President, Principal Financial Officer and Principal Accounting Officer
10.10K
--
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
6.09K
+59.09%
Dr. Roger Hajjar, M.D.
Dr. Roger Hajjar, M.D.
Independent Director
Independent Director
4.96K
+72.61%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
2.23K
+76.13%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
57.73K
-5.05%
Mr. Stephen H. (Steve) Willard, Esq.
Mr. Stephen H. (Steve) Willard, Esq.
Chief Executive Officer
Chief Executive Officer
56.43K
-3.52%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
54.71K
-4.61%
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
54.25K
+52.72%
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
33.27K
-6.76%
Mr. Nirav S. Jhaveri
Mr. Nirav S. Jhaveri
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
29.26K
-2.54%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Longeveron Inc?
Los cinco principales accionistas de Longeveron Inc son: Dr. Nataliya Agafonova, M.D.
¿Cuántas instituciones poseen acciones de Longeveron Inc (LGVN)?
A fecha de 2026Q1, 62 instituciones poseen acciones de Longeveron Inc, con un valor de mercado combinado de aproximadamente 2.25M, lo que representa el 8.08% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1131825.00.